Kevork Kazanjian, MD
Colon & Rectal Surgery · Los Angeles, CANPI 1053591941
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,000 of the $37,036 with a category attached, or 62.1%. Intuitive Surgical accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $12,204 and has fallen 61.8% since, to $4,658 in 2025. Among colon & rectal surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $480.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$37K
- Olympus America Inc.$98
- Baxter Healthcare$26
What the payments were for
- Speaking & faculty fees$23,00062%
- Travel & lodging$4,44812%
- Food & beverage$2,3886%
- Education$7,00019%
- Gifts$2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 75 | $36,912 |
| Olympus America Inc. | 1 | $98 |
| Baxter Healthcare | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$33,355
- DA VINCI SP$2,150
How this compares
$37,036 in reported general payments places this provider in the 90th percentile of 176 colon & rectal surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 11 | $1,288 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 33 | $435 |
| Neomycin Sulfate | 40 | $199 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $167 |
| Metronidazole | 41 | $80 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Los Angeles
- Sang LeeLos Angeles$2.4M
- Alessio PigazziLos Angeles$100K
- Joongho ShinLos Angeles$25K
- Clifford KoLos Angeles$24K
- Sarah KollerLos Angeles$16K
- Anne LinLos Angeles$14K
- Christine HsiehLos Angeles$11K
- Marjun DuldulaoLos Angeles$11K
- Glenn AultLos Angeles$11K
- Kyle CologneLos Angeles$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.